BioMarin Pharmaceutical Inc. (VIE:BMRN)
Austria · Delayed Price · Currency is EUR | Market Cap | 10.95B +22.7% |
| Revenue (ttm) | 2.98B +11.2% |
| Net Income | 63.87M -88.9% |
| EPS | 0.33 -88.9% |
| Shares Out | n/a |
| PE Ratio | 171.50 |
| Forward PE | 10.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Open | 56.76 |
| Previous Close | 55.72 |
| Day's Range | 56.48 - 56.90 |
| 52-Week Range | 42.77 - 61.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial numbers in USD Financial StatementsNews
BioMarin Pharmaceutical Transcript: Citigroup’s Biopharma Back to School Summit 2026
Key priorities include expanding blockbuster therapies and leveraging recent acquisitions for growth. Pipeline advances feature VOXZOGO's strong performance, new indications, and innovative assets like BMN 333 and ALE-01. AI tools are streamlining R&D and patient identification.
BioMarin Pharmaceutical Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Significant portfolio expansion and strong financial growth were highlighted, with new assets from the Amicus acquisition expected to drive substantial revenue and EPS accretion. VOXZOGO remains a key growth driver, while promising pipeline developments and global expansion underpin long-term strategy.
BioMarin Pharmaceutical Transcript: Wells Fargo 21st Annual Healthcare Conference
Metabolic and skeletal franchises are driving robust growth, with VOXZOGO and Amicus products expanding globally and new settlements clearing competitive hurdles. The pipeline is advancing with promising data in hypochondroplasia, BMN 333, and other assets, while commercial execution and international expansion remain key priorities.
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual ...
BioMarin to Participate in Upcoming Investor Conferences
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, Septem...
BioMarin Announces Close of the Alesta Therapeutics Acquisition
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today...
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced th...
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones. Alesta Therapeutic's lead drug is a potential treatment for hypophosphatas...
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to spin out all non-ALE1 assets to a new entity and Alesta employees to ...
BioMarin Pharmaceutical Transcript: Canaccord Genuity's 46th Annual Growth Conference
A rare disease-focused company reported strong Q2 growth, raised full-year guidance, and accelerated its de-leveraging timeline following the Amicus acquisition. Key growth drivers include global expansion of new assets, VOXZOGO's performance, and a robust pipeline, with continued focus on strategic business development.
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesda...
BioMarin Pharmaceutical Earnings Call Transcript: Q2 2026
Q2 revenue grew 20% year-over-year to nearly $1 billion, driven by strong commercial execution and the successful Amicus integration. Raised full-year guidance for revenue and EPS, with VOXZOGO, GALAFOLD, and POMBILITI/OPFOLDA all on track for blockbuster status. Integration synergies and pipeline progress support a robust outlook.
BioMarin Pharmaceutical Slides: Q2 2026
BioMarin Pharmaceutical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
BioMarin Pharmaceutical Earnings release: Q2 2026
BioMarin Pharmaceutical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
BioMarin Pharmaceutical Quarterly report: Q2 2026
BioMarin Pharmaceutical has published its Q2 2026 quarterly earnings report on August 6, 2026.
BioMarin Reports Second Quarter 2026 Financial and Operating Results
Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted ...
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a confe...
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense experti...
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm...
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented fo...
BioMarin Pharmaceutical Transcript: AGM 2026
The meeting established a quorum and proceeded with four proposals, including director elections, auditor ratification, executive compensation, and an equity plan amendment. All proposals passed by majority vote, with final results to be published in a Form 8-K.
BioMarin's drug shows significant growth gains in children in late-stage trial
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study and sending shar...
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at we...
BioMarin's genetic disease therapy shows mixed results in late-stage study
BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study.
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration...